Tango Therapeutics (TNGX) Competitors $6.54 -0.08 (-1.13%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNGX vs. KYMR, RARE, IMVT, ALVO, CRNX, MIRM, CPRX, GMTX, OGN, and AMRXShould you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Organon & Co. (OGN), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry. Tango Therapeutics vs. Its Competitors Kymera Therapeutics Ultragenyx Pharmaceutical Immunovant Alvotech Crinetics Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics Organon & Co. Amneal Pharmaceuticals Tango Therapeutics (NASDAQ:TNGX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Which has more risk and volatility, TNGX or KYMR? Tango Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Is TNGX or KYMR more profitable? Kymera Therapeutics has a net margin of -409.07% compared to Tango Therapeutics' net margin of -599.11%. Kymera Therapeutics' return on equity of -30.11% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-599.11% -79.72% -49.30% Kymera Therapeutics -409.07%-30.11%-25.65% Does the media refer more to TNGX or KYMR? In the previous week, Tango Therapeutics had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Tango Therapeutics and 8 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.97 beat Tango Therapeutics' score of 0.63 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of TNGX or KYMR? 79.0% of Tango Therapeutics shares are held by institutional investors. 7.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend TNGX or KYMR? Tango Therapeutics currently has a consensus price target of $10.33, suggesting a potential upside of 58.12%. Kymera Therapeutics has a consensus price target of $59.11, suggesting a potential upside of 47.48%. Given Tango Therapeutics' higher probable upside, equities research analysts plainly believe Tango Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 3.10 Which has better earnings and valuation, TNGX or KYMR? Tango Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$24.30M29.16-$130.30M-$1.33-4.91Kymera Therapeutics$47.07M55.45-$223.86M-$3.10-12.93 SummaryKymera Therapeutics beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks. Get Tango Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNGX vs. The Competition Export to ExcelMetricTango TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$711.07M$2.98B$5.44B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-4.9318.0530.0425.06Price / Sales29.16175.18373.4277.08Price / CashN/A41.8335.9458.58Price / Book5.407.218.125.67Net Income-$130.30M-$54.43M$3.25B$265.39M7 Day Performance0.08%0.07%0.96%2.54%1 Month Performance14.65%5.29%2.69%1.89%1 Year Performance-26.66%9.94%28.08%24.09% Tango Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNGXTango Therapeutics1.9442 of 5 stars$6.54-1.1%$10.33+58.1%-24.2%$711.07M$24.30M-4.9390News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionKYMRKymera Therapeutics3.4593 of 5 stars$43.66+1.6%$59.11+35.4%+1.3%$2.80B$47.07M-14.08170Upcoming EarningsRAREUltragenyx Pharmaceutical4.4016 of 5 stars$28.46+0.1%$83.25+192.5%-43.1%$2.69B$560.23M-4.841,294Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionIMVTImmunovant1.5403 of 5 stars$16.09+2.4%$36.40+126.2%-41.7%$2.69BN/A-5.87120Positive NewsALVOAlvotech2.8588 of 5 stars$8.87+0.9%$14.00+57.8%-23.3%$2.65B$491.98M23.971,032CRNXCrinetics Pharmaceuticals3.322 of 5 stars$28.22+1.4%$69.50+146.3%-42.3%$2.61B$1.04M-7.39210Earnings ReportMIRMMirum Pharmaceuticals3.3513 of 5 stars$52.24+0.4%$65.50+25.4%+53.5%$2.58B$336.89M-32.45140Trending NewsEarnings ReportAnalyst ForecastCPRXCatalyst Pharmaceuticals4.8868 of 5 stars$21.73+2.9%$32.83+51.1%+21.0%$2.58B$491.73M13.8480GMTXGemini TherapeuticsN/A$58.97-1.3%N/A+40.1%$2.56BN/A-58.9730Gap DownOGNOrganon & Co.4.8395 of 5 stars$9.68-0.7%$18.00+86.0%-52.2%$2.53B$6.40B3.364,000Earnings ReportDividend AnnouncementHigh Trading VolumeAMRXAmneal Pharmaceuticals3.6293 of 5 stars$7.96+1.7%$11.60+45.7%+20.6%$2.45B$2.79B-198.958,100Earnings Report Related Companies and Tools Related Companies KYMR Competitors RARE Competitors IMVT Competitors ALVO Competitors CRNX Competitors MIRM Competitors CPRX Competitors GMTX Competitors OGN Competitors AMRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNGX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
